Cardio-selective medications, including angiotensin-converting enzyme (ACE) inhibitors—both centrally active and non-centrally active—and angiotensin receptor blockers (ARBs), have been investigated for cognitive benefits in heart failure (HF) patients. This secondary analysis of a cross-sectional study involved 90 community-dwelling adults with HF screened for cognitive impairment using the Montreal Cognitive Assessment (MoCA), with a mean score of 24.73 (SD = 2.76). T-tests revealed a significant association between ACE inhibitor use (78% of participants) and MoCA scores (p = 0.01), particularly for centrally active ACE inhibitors (60%), while no association was observed with ARB use. Bivariate analysis indicated that higher ACE inhibitor dosages correlated with improved cognitive function (r = 0.211, p = 0.046). In a multiple regression model adjusting for age, education, heart failure medication knowledge, and mean arterial blood pressure, ACE inhibitor use contributed an additional 4.1% to the explained variance in cognitive function and remained statistically significant (p = 0.021). Age and mean arterial blood pressure were not significant in the final model. These findings suggest a protective cognitive effect of ACE inhibitors in HF patients and support further investigation into their potential role in mitigating cognitive decline.
Sarah E. Montgomery (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: